Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Apr-24 5:45 PM View:  | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 15-Apr-24 | Option Exercise | 19,582 | $19.12 | $374,408.00 | 5% 408.12K to 427.7K | |
| 17-Apr-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 15-Apr-24 | Planned Option Sale | 19,582 | $59.91 | $1,173,230.00 | (5%) 427.7K to 408.12K | |
| 18-Mar-24 5:45 PM View: | Prasad Raju Chief Financial Officer | Crispr Therapeutics Ag (CRSP) | 15-Mar-24 | Option Sale | 3,524 | $72.69 | $256,160.00 | (35%) 10.0K to 6.48K | |
| 18-Mar-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 15-Mar-24 | Option Exercise | 20,000 | $19.12 | $382,400.00 | 5% 408.12K to 428.12K | |
| 18-Mar-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 15-Mar-24 | Planned Option Sale | 20,000 | $72.48 | $1,449,630.00 | (5%) 428.12K to 408.12K | |
| 18-Mar-24 5:45 PM View: | Prasad Raju Chief Financial Officer | Crispr Therapeutics Ag (CRSP) | 14-Mar-24 | Option Exercise | 10,000 | -- | -- | 100% 0 to 10.0K | |
| 12-Mar-24 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 12-Mar-24 | Option Sale | 1,146 | $74.44 | $85,308.20 | (2%) 62.32K to 61.17K | |
| 12-Mar-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 12-Mar-24 | Option Sale | 4,583 | $74.44 | $341,159.00 | (1%) 412.7K to 408.12K | |
| 12-Mar-24 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 11-Mar-24 | Option Sale | 2,801 | $78.26 | $219,206.00 | (4%) 65.12K to 62.32K | |
| 12-Mar-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 11-Mar-24 | Option Sale | 9,802 | $78.26 | $767,105.00 | (2%) 422.51K to 412.7K | |
| 12-Mar-24 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 11-Mar-24 | Option Exercise | 2,250 | -- | -- | 4% 62.87K to 65.12K | |
| 12-Mar-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 11-Mar-24 | Option Exercise | 9,000 | -- | -- | 2% 413.51K to 422.51K | |
| 12-Mar-24 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 10-Mar-24 | Option Exercise | 5,500 | -- | -- | 10% 57.37K to 62.87K | |
| 12-Mar-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 10-Mar-24 | Option Exercise | 19,250 | -- | -- | 5% 394.26K to 413.51K | |
| 27-Feb-24 6:39 PM View: | George Simeon Director | Crispr Therapeutics Ag (CRSP) | 27-Feb-24 | Grant | 1,048,950 | $71.50 | $75,000,000.00 | 100% 0 to 1.05M | (3%) |
| 21-Feb-24 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 20-Feb-24 | Option Sale | 1,913 | $79.67 | $152,409.00 | (3%) 59.28K to 57.37K | |
| 21-Feb-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 20-Feb-24 | Option Sale | 6,370 | $79.67 | $507,498.00 | (2%) 400.63K to 394.26K | |
| 21-Feb-24 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 18-Feb-24 | Option Exercise | 3,825 | -- | -- | 7% 55.46K to 59.28K | |
| 21-Feb-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 18-Feb-24 | Option Exercise | 13,250 | -- | -- | 3% 387.38K to 400.63K | |
| 16-Feb-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 15-Feb-24 | Option Exercise | 20,000 | $19.12 | $382,400.00 | 5% 387.38K to 407.38K | |
| 16-Feb-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 15-Feb-24 | Planned Option Sale | 20,000 | $80.36 | $1,607,180.00 | (5%) 407.38K to 387.38K | |
| 31-Jan-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 29-Jan-24 | Option Exercise | 50,000 | $19.12 | $956,000.00 | 13% 387.38K to 437.38K | |
| 31-Jan-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 29-Jan-24 | Planned Option Sale | 50,000 | $60.51 | $3,025,570.00 | (11%) 437.38K to 387.38K | |
| 18-Jan-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 16-Jan-24 | Option Exercise | 20,000 | $19.12 | $382,400.00 | 5% 387.38K to 407.38K | |
| 18-Jan-24 5:45 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 16-Jan-24 | Planned Option Sale | 20,000 | $62.50 | $1,250,060.00 | (5%) 407.38K to 387.38K | |
| 01-Jun-23 5:44 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 30-May-23 | Planned Option Sale | 25,000 | $64.88 | $1,621,890.00 | (6%) 412.38K to 387.38K | |
| 01-Jun-23 5:44 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 30-May-23 | Option Exercise | 25,000 | $19.12 | $478,000.00 | 6% 387.38K to 412.38K | |
| 25-May-23 5:35 PM View: | Morrow Phuong Khanh Chief Medical Officer | Crispr Therapeutics Ag (CRSP) | 24-May-23 | Payment of Exercise | 2,527 | $65.91 | $166,555.00 | (36%) 6.94K to 4.41K | |
| 25-May-23 5:35 PM View: | Morrow Phuong Khanh Chief Medical Officer | Crispr Therapeutics Ag (CRSP) | 23-May-23 | Option Exercise | 6,938 | -- | -- | 100% 0 to 6.94K | |
| 27-Apr-23 5:37 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 25-Apr-23 | Option Exercise | 25,000 | $19.12 | $478,000.00 | 6% 387.38K to 412.38K | |
| 27-Apr-23 5:37 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 25-Apr-23 | Planned Option Sale | 25,000 | $50.67 | $1,266,640.00 | (6%) 412.38K to 387.38K | |
| 31-Mar-23 5:49 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 29-Mar-23 | Option Exercise | 25,000 | $19.12 | $478,000.00 | 6% 387.38K to 412.38K | |
| 31-Mar-23 5:49 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 29-Mar-23 | Planned Option Sale | 25,000 | $44.46 | $1,111,500.00 | (6%) 412.38K to 387.38K | |
| 14-Mar-23 5:47 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 13-Mar-23 | Payment of Exercise | 9,444 | $43.22 | $408,170.00 | (2%) 396.82K to 387.38K | |
| 14-Mar-23 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 13-Mar-23 | Payment of Exercise | 2,305 | $43.22 | $99,622.10 | (4%) 57.15K to 54.84K | |
| 14-Mar-23 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 11-Mar-23 | Option Exercise | 2,250 | -- | -- | 4% 53.62K to 55.87K | |
| 14-Mar-23 5:47 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 11-Mar-23 | Option Exercise | 9,000 | -- | -- | 2% 382.46K to 391.46K | |
| 14-Mar-23 5:45 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 10-Mar-23 | Option Exercise | 2,833 | -- | -- | 5% 52.07K to 54.9K | |
| 14-Mar-23 5:47 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 10-Mar-23 | Option Exercise | 11,833 | -- | -- | 3% 375.99K to 387.82K | |
| 01-Mar-23 6:11 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 27-Feb-23 | Option Exercise | 25,000 | $19.12 | $478,000.00 | 7% 375.99K to 400.99K | |
| 01-Mar-23 6:11 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 27-Feb-23 | Planned Option Sale | 25,000 | $48.25 | $1,206,240.00 | (6%) 400.99K to 375.99K | |
| 22-Feb-23 5:41 PM View: | Smith Brendan Chief Financial Officer | Crispr Therapeutics Ag (CRSP) | 21-Feb-23 | Payment of Exercise | 1,392 | $48.26 | $67,177.90 | (22%) 6.46K to 5.07K | |
| 22-Feb-23 5:35 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 21-Feb-23 | Payment of Exercise | 1,950 | $48.26 | $94,107.00 | (4%) 54.02K to 52.07K | |
| 22-Feb-23 5:38 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 21-Feb-23 | Payment of Exercise | 6,373 | $48.26 | $307,561.00 | (2%) 382.36K to 375.99K | |
| 22-Feb-23 5:41 PM View: | Smith Brendan Chief Financial Officer | Crispr Therapeutics Ag (CRSP) | 18-Feb-23 | Option Exercise | 3,825 | -- | -- | 145% 2.64K to 6.46K | |
| 22-Feb-23 5:35 PM View: | Kasinger James R. General Counsel and Secretary | Crispr Therapeutics Ag (CRSP) | 18-Feb-23 | Option Exercise | 3,825 | -- | -- | 8% 50.19K to 54.02K | |
| 22-Feb-23 5:38 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 18-Feb-23 | Option Exercise | 13,250 | -- | -- | 4% 369.11K to 382.36K | |
| 31-Jan-23 5:34 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 27-Jan-23 | Planned Option Sale | 25,000 | $51.47 | $1,286,800.00 | (6%) 394.11K to 369.11K | |
| 31-Jan-23 5:34 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 27-Jan-23 | Option Exercise | 25,000 | $19.12 | $478,000.00 | 7% 369.11K to 394.11K | |
| 30-Dec-22 5:33 PM View: | Kulkarni Samarth Chief Executive Officer Director | Crispr Therapeutics Ag (CRSP) | 28-Dec-22 | Option Exercise | 25,000 | $19.12 | $478,000.00 | 7% 369.11K to 394.11K |
